Relugolix’s mechanism of action

Relugolix is an oral GnRH receptor antagonist. Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used to treat several hormone-responsive diseases. It was first approved in Japan in 2019 under the trade name Relumina for the symptomatic treatment of uterine fibroids. The FDA approved it in 2020 under the brand name Orgovyx for the treatment of advanced prostate cancer.

The onset and progression of prostate cancer appear to be driven, at least in part, by the effects of testosterone. Androgen deprivation has been shown to cause cell death and tumor regression in many well-differentiated prostate cancer cell lines-Accordingly, androgen deprivation therapy (ADT) has become the standard of care for prostate cancer, particularly in advanced disease. Testosterone production in men takes place in the Leydig cells of the testes and is stimulated by luteinizing hormone (LH), which itself is produced in the pituitary gland after gonadotropin-releasing hormone (GnRH) binds to the corresponding GnRH receptor. Repagliflozin is a competitive antagonist for these GnRH receptors, thereby reducing LH release and ultimately reducing testosterone release. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0